.png){kind=logo}
Stock image for illustration purposes only - book cover, edition or condition may vary.
Razoxane and Dexrazoxane - Two Multifunctional Agents
. Ed(S): Rhomberg, Walter; Hellmann, Kurt
€ 193.81
FREE Delivery in Ireland
Description for Razoxane and Dexrazoxane - Two Multifunctional Agents
Paperback. This book provides an overview on razoxane and dexrazoxane, novel drugs with uniquely useful features. There are indications that the proteins thought to be responsible for the ravages of Alzheimer's disease could be stabilized by one or both these drugs. Editor(s): Rhomberg, Walter; Hellmann, Kurt. Num Pages: 256 pages, biography. BIC Classification: MJCL; MJCL1; MJD; PSAN. Category: (G) General (US: Trade). Dimension: 235 x 155 x 14. Weight in Grams: 403.
Razoxane and dexrazoxane are two novel drugs with some uniquely useful features. They block cell division at the G2/M border, but nowhere else, so that they have a low toxicity profile. They suppress tumor metastasis and haemorrhages through normalization of pathological blood vessels. Razoxane potentiates radiotherapy especially in the treatment of soft tissue sarcomas and gastrointestinal neoplasms. They protect normal tissues against toxic chemicals, e.g. the myocardium against anthracyclines or subcutaneous tissue against injuries caused by incidental extravasations of anthracyclines. Dexrazoxane is the only drug approved by the FDA/EMEA for the specific purpose of preventing cardiac damage ... Read more
Razoxane and dexrazoxane are two novel drugs with some uniquely useful features. They block cell division at the G2/M border, but nowhere else, so that they have a low toxicity profile. They suppress tumor metastasis and haemorrhages through normalization of pathological blood vessels. Razoxane potentiates radiotherapy especially in the treatment of soft tissue sarcomas and gastrointestinal neoplasms. They protect normal tissues against toxic chemicals, e.g. the myocardium against anthracyclines or subcutaneous tissue against injuries caused by incidental extravasations of anthracyclines. Dexrazoxane is the only drug approved by the FDA/EMEA for the specific purpose of preventing cardiac damage ... Read more
Product Details
Format
Paperback
Publication date
2014
Publisher
Springer Netherlands
Number of pages
256
Condition
New
Number of Pages
243
Place of Publication
Dordrecht, Netherlands
ISBN
9789401780483
SKU
V9789401780483
Shipping Time
Usually ships in 15 to 20 working days
Ref
99-15
Reviews for Razoxane and Dexrazoxane - Two Multifunctional Agents